| 1 |
33895867 | Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. | 2021 Aug |
1 |
| 2 |
31863599 | FGF23 and the PTH response to paricalcitol in chronic kidney disease. | 2020 Feb |
2 |
| 3 |
32775985 | Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol. | 2020 Jul-Aug |
1 |
| 4 |
32855693 | Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis. | 2020 Oct |
2 |
| 5 |
30651833 | A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism. | 2019 Jan |
2 |
| 6 |
29386308 | Effects of Oral Paricalcitol and Calcitriol Treatment on Peritoneal Membrane Characteristics of Peritoneal Dialysis Patients - A Pilot Study. | 2018 May-Jun |
1 |
| 7 |
28017524 | Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels. | 2017 Mar |
1 |
| 8 |
28436117 | Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. | 2017 Aug |
2 |
| 9 |
28451892 | Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients. | 2017 Jul |
2 |
| 10 |
28976989 | Vitamin D and methylarginines in chronic kidney disease (CKD). | 2017 |
1 |
| 11 |
26705959 | The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism. | 2016 |
2 |
| 12 |
26748501 | Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. | 2016 Apr |
1 |
| 13 |
27312912 | Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population. | 2016 Jun |
1 |
| 14 |
27737389 | Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective. | 2016 Jul-Sep |
1 |
| 15 |
26306956 | Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. | 2015 |
2 |
| 16 |
23713876 | Vitamin D metabolites and/or analogs: which D for which patient? | 2014 Mar |
1 |
| 17 |
23713879 | Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol). | 2014 Mar |
1 |
| 18 |
24511210 | Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. | 2014 |
1 |
| 19 |
25029424 | Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. | 2014 Sep |
1 |
| 20 |
25095656 | [Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease]. | 2014 |
2 |
| 21 |
23364628 | Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. | 2013 Jan 18 |
6 |
| 22 |
23364629 | Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. | 2013 Jan 18 |
1 |
| 23 |
23509710 | Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. | 2013 |
2 |
| 24 |
26019845 | Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study. | 2013 Apr |
1 |
| 25 |
22702445 | Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. | 2012 |
1 |
| 26 |
23186077 | Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. | 2012 Nov 27 |
1 |
| 27 |
21603158 | The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control. | 2011 |
1 |
| 28 |
21625104 | Restoring the physiology of vitamin D receptor activation and the concept of selectivity. | 2011 |
1 |
| 29 |
21832979 | No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. | 2011 Oct |
1 |
| 30 |
22040818 | [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism]. | 2011 Nov |
1 |
| 31 |
22130286 | Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease. | 2011 |
1 |
| 32 |
20016142 | Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. | 2010 |
1 |
| 33 |
20151157 | New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. | 2010 Apr |
1 |
| 34 |
20671742 | Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. | 2010 Aug |
1 |
| 35 |
19141997 | Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? | 2009 |
1 |
| 36 |
19229819 | Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. | 2009 Jan-Feb |
1 |
| 37 |
19494616 | Importance of vitamin D receptor activation in clinical practice. | 2009 |
2 |
| 38 |
17914251 | Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. | 2008 |
1 |
| 39 |
18238737 | Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. | 2008 Jan-Feb |
1 |
| 40 |
18393917 | Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. | 2008 Apr |
1 |
| 41 |
18701614 | Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. | 2008 Nov |
2 |
| 42 |
17183255 | Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. | 2007 Jan |
1 |
| 43 |
17389886 | Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. | 2007 Apr |
1 |
| 44 |
17605511 | Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. | 2007 Jun |
1 |
| 45 |
16724654 | Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. | 2006 May |
1 |
| 46 |
16797393 | Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. | 2006 Jul |
1 |
| 47 |
17002490 | Oral paricalcitol. | 2006 |
3 |
| 48 |
15733015 | Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. | 2005 |
3 |
| 49 |
15898824 | Spotlight on paricalcitol in secondary hyperparathyroidism. | 2005 |
3 |
| 50 |
15960147 | Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. | 2005 Jun |
1 |